Filipinas - inglés - FDA (Food And Drug Administration)

 ; importer:  ; distributor:   - tetanus and diphtheria toxoids adsorbed combined with component acellular pertussis vaccine - solution for injection (im) - formulation: each dose (0.5 ml) contains: diphtheria toxoid adsorbed-2 lf tetanus toxoid adsorbed- 5lf component acellular pertussis pertussis toxoid adsorbed-2.5 mcg filamentous haemagglutinin adsorbed-5 mcg fimbriae types 2 and 2 adsorbed-5 mcg pertactin adsorbed-5 mcg

Filipinas - inglés - FDA (Food And Drug Administration)

genpharm, inc.; distributor: genpharm, inc. - tetanus toxoid (adsorbed) - suspension for injection (im) - 5 lf per 0.5ml

Irlanda - inglés - Ecolab

ecolab deutschland gmbh -

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu; haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)); hepatitis b virus surface antigen 10ug; pertussis filamentous haemagglutinin 25ug (adsorbed); pertussis toxoid, adsorbed 25ug; polio virus type 1 40 dagu (mahoney); polio virus type 2 8 dagu (mef-1); polio virus type 3 32 dagu (saukett); tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu - suspension for injection - active: diphtheria toxoid, adsorbed 30 lf u equivalent to not less than 20 iu haemophilus influenzae type b polysaccharide 12ug ((polyribosylribitol phosphate) conjugated to tetanus protein (22-36 mcg)) hepatitis b virus surface antigen 10ug pertussis filamentous haemagglutinin 25ug (adsorbed) pertussis toxoid, adsorbed 25ug polio virus type 1 40 dagu (mahoney) polio virus type 2 8 dagu (mef-1) polio virus type 3 32 dagu (saukett) tetanus toxoid, adsorbed 10 lf u equivalent to not less than 40 iu excipient: aluminium hydroxide amino acids dibasic sodium phosphate monobasic potassium phosphate sucrose trometamol water for injection - hexaxim is indicated for vaccination of infants from six weeks of age against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive infections caused by haemophilus influenzae type b. use of this vaccine should be in accordance with the national recommendation as per the current immunisation handbook.

Nueva Zelanda - inglés - Ministry for Primary Industries

elanco australasia pty ltd - silicon oestradiol suspension (20%) - silicon oestradiol suspension (20%) 366.1 g/kg - hormonal growth promotant

Canadá - inglés - Health Canada

glaxosmithkline inc - paroxetine (paroxetine hydrochloride) - tablet (extended-release) - 37.5mg - paroxetine (paroxetine hydrochloride) 37.5mg - selective-serotonin reuptake inhibitors

Taiwán - inglés - Ecolab

ecolab deutschland gmbh -

Estados Unidos - inglés - NLM (National Library of Medicine)

sanofi pasteur inc. - clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - clostridium tetani toxoid antigen (formaldehyde inactivated) 5 [lf] in 0.5 ml - adacel® is a vaccine indicated for: - active booster immunization against tetanus, diphtheria and pertussis. adacel is approved for use in individuals 10 through 64 years of age. immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age. a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid, diphtheria toxoid or pertussis containing vaccine or any other component of this vaccine is a contraindication to administration of adacel. [see description (11). ] because of uncertainty as to which component of the vaccine may be responsible, none of the components should be administered. alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered. encephalopathy (e.g., coma, prolonged seizures, or decreased level of consciousness) within 7 days of a previous dose of a pertussis containing vaccine not attributable to another identifiable cause is a contraindicatio

Estados Unidos - inglés - NLM (National Library of Medicine)

actavis pharma, inc. - pilocarpine hydrochloride (unii: 0ww6d218xj) (pilocarpine - unii:01mi4q9di3) - pilocarpine hydrochloride 5 mg - pilocarpine hydrochloride tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with sjogren's syndrome. pilocarpine hydrochloride tablets are contraindicated in patients with uncontrolled asthma, known hypersensitivity to pilocarpine, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle closure) glaucoma.

Reino Unido - inglés - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - hydrocortisone - oral tablet - 10mg